SLC5A2 and chronic kidney disease: Across the overall population and within each racial and ethnic group, the cost-effectiveness of population-wide screening was driven by the effectiveness of SGLT2 inhibitors in reducing all-cause mortality and slowing CKD progression, eGFR stage–specific quality-of-life weights, SGLT2 inhibitor and conventional CKD therapy costs, and treatment initiation after screening (eFigures 6-8 in Supplement 1).